• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用定制施源器优化表面模具近距离放射治疗鼻基底细胞癌。

Optimizing surface mould brachytherapy for treatment of nasal basal cell carcinoma using customized applicators.

作者信息

Barnes Elizabeth A, Tsao May N, Taggar Amandeep S, Ravi Ananth, Paudel Moti R

机构信息

Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

出版信息

Brachytherapy. 2023 Sep-Oct;22(5):665-672. doi: 10.1016/j.brachy.2023.05.001. Epub 2023 Jun 3.

DOI:10.1016/j.brachy.2023.05.001
PMID:37277286
Abstract

PURPOSE

Surface mould brachytherapy (SMBT) is ideal in treating superficial skin cancer over the curved surface of the nasal ala. We describe the process of initiating and optimizing SMBT treatment at our institution including clinical workflow, generation of three dimensional (3D) printed custom applicators, and clinical outcomes.

METHODS AND MATERIALS

Planning CT scans were used to acquire images for delineating target volumes. The applicator was designed with customized catheter positioning (3-5mm from target) to cover target volume while sparing dose to organs at risk (OAR) such as adjacent skin and nasal mucosa. Applicators were 3D printed, with transparent resin to aid visualization of underlying skin. Dosimetric parameters evaluated included CTV D90, CTV D0.1cc, and D2cc to OARs. Clinical outcomes assessed were local control, acute and late toxicity (Common Terminology Criteria for Adverse Events v5.0 [CTCAEv5.0]), and cosmesis (Radiation Therapy Oncology Group [RTOG]).

RESULTS

Ten patients were treated with SMBT with a median followup of 17.8 months. Dose prescription was 40 Gy in 10 daily fractions. Mean CTV D90 was 38.5 Gy (range 34.7-40.6), mean CTV D0.1cc 49.2 Gy (range 45.6-53.5), which was <140% of the prescription dose in all patients. Treatment was well tolerated, with acceptable Grade 2 acute, Grade 0-1 late skin toxicity, and good-excellent cosmesis for all patients. Two patients experienced local failure, and both underwent surgical salvage.

CONCLUSIONS

SMBT was successfully planned and delivered for superficial nasal BCC using 3D printed custom applicators. Excellent target coverage was achieved while minimizing dose to OAR. Toxicity and cosmesis rates were good-excellent.

摘要

目的

表面模具近距离放射治疗(SMBT)是治疗鼻翼曲面浅表皮肤癌的理想方法。我们描述了在我们机构启动和优化SMBT治疗的过程,包括临床工作流程、三维(3D)打印定制施源器的制作以及临床结果。

方法和材料

使用计划CT扫描获取图像以勾画靶区体积。施源器设计为定制导管定位(距靶区3 - 5毫米),以覆盖靶区体积,同时减少对周围皮肤和鼻黏膜等危及器官(OAR)的剂量。施源器采用透明树脂进行3D打印,以帮助观察深部皮肤。评估的剂量学参数包括CTV D90、CTV D0.1cc以及OAR的D2cc。评估的临床结果包括局部控制、急性和晚期毒性(不良事件通用术语标准第5.0版[CTCAEv5.0])以及美容效果(放射治疗肿瘤学组[RTOG])。

结果

10例患者接受了SMBT治疗,中位随访时间为17.8个月。剂量处方为40 Gy,分10次每日给予。平均CTV D90为38.5 Gy(范围34.7 - 40.6),平均CTV D0.1cc为49.2 Gy(范围45.6 - 53.5),所有患者均<处方剂量的140%。治疗耐受性良好,所有患者的急性2级、晚期0 - 1级皮肤毒性可接受,美容效果良好 - 优秀。2例患者出现局部复发,均接受了手术挽救。

结论

使用3D打印定制施源器成功地对浅表鼻基底细胞癌进行了SMBT治疗计划和实施。在将OAR剂量降至最低的同时实现了出色的靶区覆盖。毒性和美容效果良好 - 优秀。

相似文献

1
Optimizing surface mould brachytherapy for treatment of nasal basal cell carcinoma using customized applicators.使用定制施源器优化表面模具近距离放射治疗鼻基底细胞癌。
Brachytherapy. 2023 Sep-Oct;22(5):665-672. doi: 10.1016/j.brachy.2023.05.001. Epub 2023 Jun 3.
2
A dosimetric comparison of CT- and photogrammetry- generated 3D printed HDR brachytherapy surface applicators.CT 与摄影测量生成 3D 打印 HDR 近距离放射治疗表面施源器的剂量学比较。
Phys Eng Sci Med. 2022 Mar;45(1):125-134. doi: 10.1007/s13246-021-01092-1. Epub 2022 Jan 12.
3
Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer.近距离放疗中高危临床靶区体积变化的动力学及其对不可手术宫颈癌患者靶区覆盖的影响。
Neoplasma. 2018 Mar 14;65(3):425-430. doi: 10.4149/neo_2018_170113N30.
4
Development and dosimetric assessment of a patient-specific elastic skin applicator for high-dose-rate brachytherapy.用于高剂量率近距离放射治疗的患者特异性弹性皮肤施源器的开发与剂量学评估
Brachytherapy. 2019 Mar-Apr;18(2):224-232. doi: 10.1016/j.brachy.2018.11.001. Epub 2018 Dec 7.
5
Efficacy and safety of a 3D-printed applicator for vaginal brachytherapy in patients with central pelvic-recurrent cervical cancer after primary hysterectomy.3D 打印阴道施源器在原发性子宫切除术后中央型盆腔复发性宫颈癌患者阴道近距离放疗中的疗效和安全性。
Brachytherapy. 2022 Mar-Apr;21(2):193-201. doi: 10.1016/j.brachy.2021.11.004. Epub 2021 Dec 31.
6
Comparison of the Dosimetric Influence of Applicator Displacement on 2D and 3D Brachytherapy for Cervical Cancer Treatment.比较宫颈癌治疗中施源器位移对二维和三维近距离放疗的剂量学影响。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211041201. doi: 10.1177/15330338211041201.
7
Clinical applications of 3-dimensional printing in radiation therapy.三维打印在放射治疗中的临床应用。
Med Dosim. 2017;42(2):150-155. doi: 10.1016/j.meddos.2017.03.001. Epub 2017 May 8.
8
Clinical and toxicity outcomes with 3D based-HDR surface mold brachytherapy in skin cancer.基于三维的高剂量率表面敷贴近距离放射治疗皮肤癌的临床及毒性结果
J Cancer Res Ther. 2024 Apr 1;20(3):930-934. doi: 10.4103/jcrt.jcrt_2641_22. Epub 2024 Jun 27.
9
Can MRI-only replace MRI-CT planning with a titanium tandem and ovoid applicator?仅使用磁共振成像(MRI)能否替代使用钛制阴道施源器和卵圆形容器进行的磁共振成像-计算机断层扫描(MRI-CT)治疗计划制定?
Brachytherapy. 2018 Sep-Oct;17(5):747-752. doi: 10.1016/j.brachy.2018.05.010. Epub 2018 Jun 23.
10
Point A vs. HR-CTV D in MRI-based cervical brachytherapy of small and large lesions.基于MRI的宫颈近距离放射治疗中,小病灶和大病灶的A点与高危临床靶区D的比较。
Brachytherapy. 2016 Nov-Dec;15(6):825-831. doi: 10.1016/j.brachy.2016.08.010. Epub 2016 Sep 29.

引用本文的文献

1
Advantages of 3D printed patient-individual moulds in brachytherapy for facial skin cancer.3D打印的个体化模具在面部皮肤癌近距离放射治疗中的优势。
Strahlenther Onkol. 2025 Feb 26. doi: 10.1007/s00066-025-02372-5.
2
The Use of 3D Printing Technology in Gynaecological Brachytherapy-A Narrative Review.3D打印技术在妇科近距离放射治疗中的应用——一项叙述性综述
Cancers (Basel). 2023 Aug 18;15(16):4165. doi: 10.3390/cancers15164165.